600062.SH
华润双鹤
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.83
+1.02%Year over year
Reported trailing growth
- Revenue
- -3.7%
- EBITDA
- —
- EBIT
- -2.8%
- EPS
- -0.2%
- Free cash flow
- -32.7%
- Operating cash flow
- -24.0%
Forward estimates
Based on analyst estimates
- Revenue
- -73.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.6%
- EBITDA
- +10.0%
- EBIT
- +9.1%
- Net income
- +11.8%
- EPS
- +11.9%
- Free cash flow
- -0.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026